Dr. Jim Novick is the creator and host of the one hour weekly medical news and information show, "The Medical Hour" . Raised in Northern New Jersey, he did his
undergraduate work at Johns Hopkins, and graduated from the University of Maryland School of Medicine. Five more years at the U. of Maryland Hospital resulted in board certification, first in Internal Medicine and then in Gastroenterology. He has maintained a consultative practice of GI in Maryland for the past 30 years, currently located in Towson, Md.
In addition to his clinical practice, Dr. Novick is on the part-time faculty of The Johns Hopkins University School of Medicine. As the director of Charm City Research, he was the principal investigator of over 30 clinical trials on novel drugs for Gastroenterology, with numerous publications. From 2006 - 2008 he served as the Associate Director of Gastroenterology for the Centocor Bio-Pharma company, a division of J & J. And he currently sits on the board of directors of the Baltimore City Medical Society.
In 2012 Dr. Novick was named as one of Maryland's top GI docs by US News and World Reports.…
Miner, P.B., Fass, R., & Novick, J.S. (In preparation). Cilansetron in irritable bowel syndrome with diarrhea predominance: A randomized, double-blind, placebo-controlled trial. (2005)
Novick, J.S., Pruitt, R.E., Carter, F., Krause, G., Caras, S., & Steinborn, C. (2005). Cilansetron improves quality of life over 3 months in patients with irritable bowel syndrome with diarrhea predominance (IBS-D). Gastroenterology, 128 (4), A287-A287 Suppl. 2.
Fisher, R.S., Thistle, J., Lembo, A., Novick, J, O'Kane, P., Chey, W.D., Beglinger, C., Rueegg, P., Shi, V., Dogra, A., Luo, D., & Earnest, D.L. (2004). Tegaserod does not alter fasting or meal-induced biliary tract motility. American Journal Of Gastroenterology, 99 (7), 1342-1349.
Johanson, J.F., Wald, A., Tougas, G., Chey, W.D., Novick, J.S., Lembo, A.J., Fordham, F., Guella, M., & Nault, B. (2004). Effect of Tegaserod in chronic constipation: A randomized, double-blind, controlled trial. Clinical Gastroenterology and Hepatology, 2 (9)
Wald, A., Johanson, J., Tougas, G., Chey, W., Novick, J., Lembo, A., Fordham, F., Guella, M., & Nault, B. (2003). Safety and tolerability of Tegaserod in patients treated for chronic constipation (CC): A 12-week, double-blind, placebo-controlled multicenter study performed in the Americas. Gasteronterology, 124 (4), A573-A573 Suppl.
Novick, J., Miner, P., Krause, R., Glebas, K., Bliesath, H., Ligozio, G., Ruegg, P., & Lefkowitz, M. (2002). A randomized, double-blind, placebo-controlled trial of Tegaserod in female patients suffering from irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics, 16 (11), 1877-1888.
Lebowitz, E.A., Novick, J.S., Rudolph, A.M. (1972). Development of myocardial sympathetic innervation in fetal lamb. Pediatric Research, 6 (12) , 887-893 1972.
Lebowitz, E.A., Novick, J.S., & Rudolph, A.M. (1971). Efferent sympathetic development in fetal lamb heart. Circulation, 44 (4), 51.